- AstraZeneca’s full-year Core EPS for 2024 came in at $8.21, slightly above the market estimate of $8.19.
- In the fourth quarter, Core EPS was $2.09, surpassing the estimate of $2.06.
- The company’s Core operating profit was $4.20 billion, just missing the projected $4.29 billion.
- Core operating margin stood at 28%, slightly below the expected 30%.
- Core gross profit was reported at $12.09 billion, exceeding the forecast of $11.66 billion.
- Core gross margin was 79%, which did not meet the estimated 81%.
- Revenue reached $14.89 billion, beating the expected figure of $14.21 billion.
- Collaboration revenue amounted to $815 million, significantly above the estimate of $533.3 million.
- Alliance revenue was $714 million, also exceeding the projected $610.7 million.
- Product sales were reported at $13.36 billion, slightly higher than the estimate of $13.14 billion.
- Research and Development expenses were notably high at $4.68 billion, compared to the estimate of $3.26 billion.
- Sales, General and Administrative expenses were $5.41 billion, exceeding the projected $4.98 billion.
- AstraZeneca has issued its Total Revenue and Core EPS guidance for FY 2025 at constant exchange rates (CER), using average rates from 2024 as a reference.
- Should exchange rates from February 2025 to December 2025 remain as they were in January 2025, Total Revenue is expected to face a low single-digit percentage adverse impact, while Core EPS might encounter a mid-single-digit percentage adverse impact.
- The investment consensus includes 25 buy ratings, 6 holds, and no sell recommendations.
“`
A look at AstraZeneca PLC Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 2 | |
| Dividend | 3 | |
| Growth | 5 | |
| Resilience | 2 | |
| Momentum | 4 | |
| OVERALL SMART SCORE | 3.2 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
According to Smartkarma Smart Scores, AstraZeneca PLC, a pharmaceutical holding company, shows a promising long-term outlook. With a strong emphasis on growth and momentum, scoring 5 and 4 respectively in these areas, the company appears to be on a positive trajectory. AstraZeneca’s focus on research, manufacturing, and sale of pharmaceutical and medical products across various therapeutic areas positions it well for future expansion and innovation. While the value and resilience scores are somewhat lower at 2 each, the dividend and momentum scores stand at a respectable 3 and 4, indicating stability and growth potential in the company.
Operating in key therapeutic areas like oncology and cardiovascular health, AstraZeneca PLC demonstrates a diversified business portfolio. With a solid growth score and momentum, the company appears well-positioned to capitalize on future opportunities in the pharmaceutical industry. While there may be room for improvement in terms of value and resilience, AstraZeneca’s overall outlook remains positive, supported by its strategic focus on research and development in key medical sectors.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
